Upstream Advantage Batavia's HIP-Vax upstream bioprocessing capability offers a differentiator for vaccine developers and infectious disease programs seeking scalable, efficient production early in development. This supports clients from cloning through GMP manufacturing, reducing transfer risk by partnering with a single provider.

Expanded Capacity With the launch of Batavia Biomanufacturing services and the Amalia GMP-ready facility in Bilthoven, Batavia is positioned to take more programs through late-stage development and clinical manufacturing, enabling faster scale-up and broader project capacity for diverse modalities.

End-to-End CDMO The broad range of services from DNA cloning, cell line generation, process development, purification, to clinical manufacturing makes Batavia an attractive single-source partner for biotech companies aiming to streamline programs and shorten timelines in Phase I/II.

Strategic Backing Backing by CJ Group and established EU-US partnerships provide credibility, potential co-development opportunities, and access to cross-border commercialization networks that reduce market-entry barriers for clients.

Focused Market Fit With experience in vaccines, viral vaccine development, and CGT-related manufacturing, Batavia can target small- to mid-sized biotech firms in need of GMP-ready production capabilities, process optimization, and early-phase manufacturing support in Europe.